METABOLISM-CLINICAL AND EXPERIMENTAL is a premier academic journal published by W B SAUNDERS CO-ELSEVIER INC, with a distinguished history dating back to 1952. This journal serves as a vital repository of knowledge in the fields of Endocrinology, Diabetes, and Metabolism, consistently ranking in the top quartile (Q1) within these categories according to the latest metrics. With an impressive impact factor and recognized for its contributions to Biochemistry, Genetics, and Molecular Biology, it ranks #5 out of 128 in the Scopus database for Endocrinology and #11 out of 244 for Medicine related to Endocrinology, Diabetes, and Metabolism, placing it in the 95th and 96th percentiles, respectively. While the journal does not currently offer open access, it maintains rigorous peer review standards and publishes cutting-edge research that drives forward the understanding of metabolic diseases and clinical practices. By engaging with METABOLISM-CLINICAL AND EXPERIMENTAL, researchers, healthcare professionals, and students can explore groundbreaking advancements and pivotal findings that shape the future of metabolic health.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Nature Reviews Endocrinology is a premier journal published by NATURE PORTFOLIO, providing comprehensive and critical reviews in the rapidly evolving field of endocrinology. Established to foster advanced understanding, it has become a vital resource for researchers, professionals, and students alike. With an impressive impact factor and a prominent ranking of Q1 in both Endocrinology and Endocrinology, Diabetes, and Metabolism categories for 2023, the journal is recognized for its high-quality research dissemination, evidenced by its rankings of #2 out of 244 in Medicine and #2 out of 128 in Biochemistry, Genetics, and Molecular Biology. Spanning the years from 2009 to 2024, it focuses on publishing cutting-edge information that shapes current scientific knowledge and clinical practices. The journal offers open access options, ensuring greater visibility and reach for its articles. Located in Germany, this journal remains at the forefront of endocrinology research, significantly contributing to the understanding of hormonal functions and their implications on health. Discover the latest advancements and insights by exploring Nature Reviews Endocrinology.

Current Obesity Reports, an esteemed journal published by SPRINGER, serves as a pivotal platform for scholars and practitioners in the field of obesity research. With its ISSN of 2162-4968, this journal has been recognized within the competitive landscape of Medicine & Internal Medicine, achieving a commendable Scopus rank of #11 out of 167, placing it in the top 93rd percentile. Launched in 2012 and covering critical developments in obesity up to 2024, this journal synthesizes innovative research, evidence-based practices, and comprehensive reviews that cater to a diverse audience, from researchers to public health professionals. While currently not offering open access options, it remains dedicated to advancing knowledge and fostering discussions that address the multifaceted issues related to obesity, its public health implications, and treatment methodologies. For those involved in tackling obesity challenges, Current Obesity Reports stands as a vital resource, contributing significantly to the discourse and scholarship in the field.

Obesity is a premier academic journal published by WILEY, dedicated to advancing knowledge in the fields of endocrinology, nutrition, and metabolism. With an impressive impact factor and ranking in the top quartile across multiple categories, including Q1 in Endocrinology, Diabetes and Metabolism, and Nutrition and Dietetics, this journal serves as a critical resource for researchers, clinicians, and policymakers. The journal facilitates the dissemination of innovative research findings spanning the biological, behavioral, and societal factors associated with obesity, offering Open Access options to ensure broad visibility and accessibility to its content. With converged years from 2006 to 2024, Obesity provides an invaluable platform for cutting-edge studies that contribute to the global understanding of obesity and its multifaceted implications for health and wellness. Located in Hoboken, New Jersey, this esteemed journal plays a pivotal role in shaping the dialogue around obesity, making it an essential read for anyone invested in tackling this pressing public health challenge.

ENDOCRINE JOURNAL, published by the Japan Endocrine Society, is a pivotal resource for researchers and professionals in the field of endocrinology, diabetes, and metabolism. With a long history dating back to 1954, this journal encompasses a comprehensive range of topics including hormonal regulation, pathophysiology of endocrine diseases, and innovative therapeutic approaches. Despite its classification as open access, the journal remains a beacon of knowledge, with impressive rankings—Q2 in Endocrinology, Diabetes and Metabolism and Q3 in Endocrinology for 2023—ensuring it is a respected source in the academic community. It serves as a critical platform for the dissemination of cutting-edge research, encouraging collaboration and facilitating advancements in understanding complex endocrine disorders. By subscribing to this journal, researchers and students gain access to seminal studies, clinical insights, and a wealth of information that drives this vital field forward.

Journal of the Endocrine Society, published by the ENDOCRINE SOC, stands as a prominent platform for disseminating significant research and findings within the field of endocrinology, diabetes, and metabolism. Established as an Open Access journal since 2017, it aims to increase the visibility and accessibility of vital scholarly contributions, allowing researchers and professionals from various backgrounds to engage with the latest insights in this rapidly evolving discipline. With an impressive Q2 ranking in Endocrinology, Diabetes and Metabolism, the journal is recognized for its impact, ranking #100 out of 244 in Scopus, highlighting its role in advancing scientific knowledge and fostering innovation. The journal, based in the United States at 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036, continues to enrich the academic landscape by converging state-of-the-art research and clinical applications through its publication cycle from 2017 to 2024. Researchers, students, and healthcare professionals are encouraged to explore this essential resource to stay at the forefront of endocrinological advancements.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.